Trial Profile
A Phase 3 Study to Assess the Immunogenicity, Safety, and Consistency of Lot Manufacture of Ross River Virus (RRV) Vaccine in Healthy Male and Female Subjects 16 Years of Age and Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 May 2018
Price :
$35
*
At a glance
- Drugs Ross River virus vaccine (Primary) ; Aluminium hydroxide
- Indications Ross River virus infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Baxter Healthcare Corporation; Ology Bioservices
- 01 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (Parent trial: NCT01242670).
- 07 Oct 2011 Planned end date changed from 1 Aug 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
- 07 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.